Silvana Di Palma

Prof. Silvana Di Palma


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2013 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
SPSilvana Di Palma
Silvana Di Palma

6 June 2013 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
KLKathryn P. Lawes
Kathryn P. Lawes
MDMartin Danford
Martin Danford
SPSilvana Di Palma
Silvana Di Palma

17 November 2015 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
INIyer Vishwas Neelakantan
Iyer Vishwas Neelakantan
SPSilvana Di Palma
Silvana Di Palma
CSC. E. T. Smith
C. E. T. Smith
AMA. McCoombe
A. McCoombe

15 November 2013 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
RKRinsey Rose Kurian
Rinsey Rose Kurian
SPSilvana Di Palma
Silvana Di Palma
ABA. W. Barrett
A. W. Barrett

Verified
Journal Article
Open access
PDF file
SPSilvana Di Palma
Silvana Di Palma
PKPanagiotis Koliou
Panagiotis Koliou
ASAlex Simonovic
Alex Simonovic
DCDaniela Costa
Daniela Costa
CFCatherine Faulkes
Catherine Faulkes
NCNadine Collins
Nadine Collins
The APIS Breast Cancer Subtyping Kit is an mRNA-based assessment of the seven parameters including three biomarkers routinely assessed in all the newly diagnosed breast cancers (BC), oestrogen receptor (ER), progesterone receptor (PR) and HER-2 and an additional four genes that create a novel proliferation signature, MKI67, PCNA, CCNA2 and KIF23. Taken together, the data are used to produce a molecular subtype for every sample. The kit was evaluated against the current standard protocol of immunohistochemistry (IHC) and/or in situ hybridisation (ISH) in breast cancer patients. The data were presented at the weekly breast multidisciplinary team (MDT) meeting. A total of 98 consecutive cases of pre-operative breast cancer core biopsies and two core biopsies of nodal metastases yielding 100 cases were assessed. IHC and APIS results were available for 100 and 99 cases. ER was concordant in 97% cases, PR was concordant in 89% and HER-2 results were concordant with IHC/ISH in 100% of the cases. Ki-67 IHC was discordant in 3% of cases when compared with MK167 alone but discordant in 24% when compared with the four-gene proliferation signature. In conclusion, our study indicates that the APIS Breast Cancer Subtyping Kit is highly concordant when compared to the results produced for ER/PR/HER-2 by IHC and/or ISH. The assay could play a role in the routine assessment of newly diagnosed breast cancer (BC) specimens.

4 January 1995
Verified
Conference Paper
Closed access
PDF file
RMRenato Marchesini
Renato Marchesini
SFSabrina Fumagalli
Sabrina Fumagalli
EPEmanuele Pignoli
Emanuele Pignoli
ASA E Sichirollo
A E Sichirollo
STStefano Tomatis
Stefano Tomatis
GBGiovanni Bottiroli
Giovanni Bottiroli
In an attempt to evaluate the role of the histological and histochemical features of adenocarcinoma and normal tissue on their fluorescence spectral patterns, we developed a Monte Carlo model to simulate the fluorescence emission from tissue. According to histology, normal colon and adenocarcinoma were considered composed of three and two tissue layers, respectively (i.e., superficial epithelium, mucosa and submucosa; tumor mass and submucosa). Characterization of the fluorescence pattern of the tissue layers as well as of several histological components was performed by spectrofluorometric analysis on ex vivo samples. Results obtained from differently modelling the morphology and histological arrangement of colon suggest the following remarks. The decrease in fluorescence intensity observed in passing from normal to abnormal tissue could be ascribed mainly to a modification in morphology. When carcinomatous tissue is involved a modification in the spectral shape is also expected.